Want to learn more? 

Let's Talk.


1. Glauber M. et al. Innovations 2016; 11(3):165-173
2. Di Eusanio M et. al. Ann Cardiothoracic Surg. 2015; 4(2):131-139
3. Gilmanov D et al. Ann Thorac Surg. 2013;96:2101-8
4. Ranucci M et al. J Heart Valve Dis. 2012 Nov;21(6):732-9
6. Late Breaking Trial LB4 - Suri R. et al. AATS 2017

* The decision of performing Valve in Valve procedures is at the discretion of the cardiologist and/or hospital's heart team, following careful assessment of the individual circumstances of each patient. Currently, no long-term data exists to support the efficacy of the procedure. Valve-in-Valve procedures in a Perceval valve should be performed according to indications provided by the transcatheter valve manufacturer.  

Learn More About Perceval
For a copy of the IFU, please contact HeartValves.US@LivaNova.com
© LivaNova 2020

Aortic Pericardial Heart Valve


Valve in Valve

Optimizing Minimally Invasive Cardiac Surgery

© LivaNova 2020

IM-02609 A

 IM-02609 A

Indication for Use:

The Perceval bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves.

Summary of Risks:

The risks or potential adverse events associated with cardiac valve replacement with a bioprosthesis include, but may not be limited to: cardiac arrhythmias, death, endocarditis, heart failure, hemorrhage, intravalvular and/or paravalvular leak, stroke or any related neurologic disorders, structural valve deterioration, reoperation and explant. Beyond the previously mentioned adverse events, specific events related to the implant of the Perceval prosthesis may include, but not be limited to dislodgment and/or migration of the prosthesis. Please refer to the product Instructions for Use (IFU) for detailed information on warnings, precautions, and potential adverse events. For a copy of the IFU, please contact: HeartValves.US@LivaNova.com

Perceval: 11 years of data, 50,000 patients treated.

The Perceval sutureless valve offers a stable, time-saving and safe surgical result, both in isolated and in combined procedures. We observe promising long-term durability given the current low incidence of SVD after 11 years of continued clinical use. 

Dr. Bart Meuris, Abstract from: Sutureless AVR Experience in a Single Centre: 11 Years of Use in 468 Patients. Oral presentation AATS 2019

Learn More About Perceval
For a copy of the IFU, please contact HeartValves.US@LivaNova.com
© LivaNova 2018

 IM-01982 A

Perceval's design was made for Minimally Invasive Cardiac Surgery. It's an innovative, sutureless and collapsible aortic bioprosthesis that allows for shorter procedures and reduced physiologic impact during surgery.4

Click HERE to read the latest press release on the safety and efficacy of Perceval and Valve in Valve Procedures

Introducing the Perceval Sutureless Surgical Valve for MICS and Complex Procedures.

Truly Sutureless

Self-expanding sutureless design reduces operative time, trauma and manipulation of aortic structures.1

Learn More
Get The 11 Year Data

For the 11 year Perceval data, please complete the form and the download will be available on the following page.